colestipol hydrochloride for oral
COLESTID Granules and FLAVORED COLESTID Granules contain colestipol hydrochloride, which is a lipid lowering agent for oral use.
Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use.
COLESTID Granules and FLAVORED COLESTID Granules are indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins [LDL] cholesterol) who do not respond adequately to diet. Generally, COLESTID and FLAVORED COLESTID have no clinically significant effect on serum triglycerides, but with its use triglyceride levels may be raised in some patients.
Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD.
According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below.
|Definite Atherosclerotic DiseaseCoronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease).||Two or More Other Risk FactorsOther risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L).||Initiation Level||Goal|
|Yes||Yes or No||≥130|
Clinical Trials Related to Colestid (Colestipol)
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction [Recruiting]
To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA
Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or
niacin. The patient’s cardiovascular risks are assessed to determine if National
Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATP III) guidelines for low
density lipoprotein (LDL) reduction were achieved between the three groups. Secondary
measures examine the safety issues with liver function test (LFT) monitoring and
rhabdomyolysis. High-density lipoproteins (HDL) elevations are monitored between the three
groups to determine efficacy as a secondary outcome.
Reports of Suspected Colestid (Colestipol) Side Effects
Drug Ineffective (13),
Abdominal Pain Upper (10),
Abdominal Distension (10),
Feeling Abnormal (6),
Drug Hypersensitivity (5),
Diarrhoea (4), more >>
Page last updated: 2006-06-05